Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obicetrapib and Cardiovascular Outcomes in ASCVD
2021-005092-39Phase 3Active
- Sponsor
- NewAmsterdam Pharma
- Start
- Jan 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease comparing Obicetrapib 10 mg with Placebo (2 arms). Started Jan 2022; status: active.
02
Drugs
obicetrapib
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on 2021-005092-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005092-39.